Posted by Michael Wonder on 29 Dec 2020
Cara Therapeutics submits new drug application to U.S. FDA for Korsuva injection in haemodialysis patients with moderate to severe pruritus
28 December 2020 - First NDA submission for Company’s lead program, Korsuva injection.
Cara Therapeutics today announced that it has submitted a new drug application to the U.S. FDA for Korsuva injection (difelikefalin) for the treatment of moderate to severe pruritus in haemodialysis patients.
